Literature DB >> 32533097

The BLIMP1-EZH2 nexus in a non-Hodgkin lymphoma.

Kimberley Jade Anderson1,2,3, Árný Björg Ósvaldsdóttir1,2,3, Birgit Atzinger1,2,3, Gunnhildur Ásta Traustadóttir1,3, Kirstine Nolling Jensen3,4,5, Aðalheiður Elín Lárusdóttir1,2,3, Jón Thór Bergthórsson2,3,6, Ingibjörg Hardardóttir3,4,5, Erna Magnúsdóttir7,8,9.   

Abstract

Waldenström's macroglobulinemia (WM) is a non-Hodgkin lymphoma, resulting in antibody-secreting lymphoplasmacytic cells in the bone marrow and pathologies resulting from high levels of monoclonal immunoglobulin M (IgM) in the blood. Despite the key role for BLIMP1 in plasma cell maturation and antibody secretion, its potential effect on WM cell biology has not yet been explored. Here we provide evidence of a crucial role for BLIMP1 in the survival of cells from WM cell line models and further demonstrate that BLIMP1 is necessary for the expression of the histone methyltransferase EZH2 in both WM and multiple myeloma cell lines. The effect of BLIMP1 on EZH2 levels is post-translational, at least partially through the regulation of proteasomal targeting of EZH2. Chromatin immunoprecipitation analysis and transcriptome profiling suggest that the two factors co-operate in regulating genes involved in cancer cell immune evasion. Co-cultures of natural killer cells and cells from a WM cell line further suggest that both factors participate in immune evasion by promoting escape from natural killer cell-mediated cytotoxicity. Together, the interplay of BLIMP1 and EZH2 plays a vital role in promoting the survival of WM cell lines, suggesting a role for the two factors in Waldenström's macroglobulinaemia.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32533097     DOI: 10.1038/s41388-020-1347-8

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  69 in total

1.  Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review.

Authors:  Robert A Kyle; Dirk R Larson; Ellen D McPhail; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; Prashant Kapoor; James R Cerhan; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2018-04-12       Impact factor: 7.616

2.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

3.  Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.

Authors:  L Xu; Z R Hunter; G Yang; Y Cao; X Liu; R Manning; C Tripsas; J Chen; C J Patterson; M Kluk; S Kanan; J Castillo; N Lindeman; S P Treon
Journal:  Leukemia       Date:  2014-02-10       Impact factor: 11.528

4.  Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study.

Authors:  Haijun Wang; Yiming Chen; Fanglin Li; Kay Delasalle; Jialei Wang; Raymond Alexanian; Larry Kwak; Luis Rustveld; Xianglin L Du; Michael Wang
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

5.  Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase.

Authors:  J Yu; C Angelin-Duclos; J Greenwood; J Liao; K Calame
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 6.  Waldenström macroglobulinemia.

Authors:  Arun Vijay; Morie A Gertz
Journal:  Blood       Date:  2007-02-15       Impact factor: 22.113

7.  PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins.

Authors:  B Ren; K J Chee; T H Kim; T Maniatis
Journal:  Genes Dev       Date:  1999-01-01       Impact factor: 11.361

Review 8.  How I treat Waldenström macroglobulinemia.

Authors:  Steven P Treon
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113

9.  Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003.

Authors:  Masako Iwanaga; Chun-Ju Chiang; Midori Soda; Mei-Shu Lai; Ya-Wen Yang; Yasushi Miyazaki; Keitaro Matsuo; Tomohiro Matsuda; Tomotaka Sobue
Journal:  Int J Cancer       Date:  2013-07-16       Impact factor: 7.396

10.  PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing.

Authors:  Ildikó Gyory; Jian Wu; György Fejér; Edward Seto; Kenneth L Wright
Journal:  Nat Immunol       Date:  2004-02-22       Impact factor: 25.606

View more
  2 in total

Review 1.  Conserved and Unique Functions of Blimp1 in Immune Cells.

Authors:  Samantha Nadeau; Gislâine A Martins
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

2.  CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.

Authors:  Ulrich Keller; Stefan Habringer; Richard Lewis; H Carlo Maurer; Nikita Singh; Irene Gonzalez-Menendez; Matthias Wirth; Markus Schick; Le Zhang; Konstandina Isaakidis; Anna Katharina Scherger; Veronika Schulze; Junyan Lu; Thorsten Zenz; Katja Steiger; Roland Rad; Leticia Quintanilla-Martinez; Marion Espeli; Karl Balabanian
Journal:  Leukemia       Date:  2021-08-06       Impact factor: 11.528

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.